Sorafenib-induced erythema multiforme

Journal of the American Academy of Dermatology

Volumn 56, Issue 3, 2007, Pages 527-528

  MacGregor, Jennifer L ^a   Silvers, David N ^a   Grossman, Marc E ^a   Sherman, William H ^b  

^a Department of Dermatology ^*

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOPLATIN; DOCETAXEL; FLT3 LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 14; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 3; VASCULOTROPIN C;

ADULT; ALOPECIA; AMELANOTIC MELANOMA; ANOREXIA; ARTICLE; BURNING SENSATION; CASE REPORT; DIARRHEA; DRUG SAFETY; ERYTHEMA MULTIFORME; FATIGUE; FEMALE; FLUSHING; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG METASTASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; STOMATITIS; TOXIC EPIDERMAL NECROLYSIS; XEROSIS;

ADMINISTRATION, ORAL; BENZENESULFONATES; ERYTHEMA MULTIFORME; FEMALE; HUMANS; LUNG NEOPLASMS; MELANOMA, AMELANOTIC; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 33847025653     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.10.981     Document Type: Article

References (5)

1. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 1-8
2. Strumberg D., Awada A., Hirte H., Clark J.W., Seeber S., Piccart P., et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: is rash associated with treatment outcome?. Eur J Cancer 42 (2006) 548-556
3. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
4. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
5. Nexavar (sorafenib) tablets 200 mg [product information]. Bayer Pharmaceuticals, West Haven, CT. Available at: http://www.univgraph.com/bayer/inserts/NexavarNAV_PI.pdf. Accessed June 29, 2006.